clinical trial · NCT07252414
GenSci143 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.·phase1·recruiting·n = 180
Advanced Solid TumorsGenSci143 for injection
brief summary
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants with Advanced Solid Tumors
started
Dec 20, 2025
primary completion
Oct 30, 2028
completion
Jun 30, 2029
last updated
Jan 5, 2026
detailed description
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants with Advanced Solid Tumors
official title
A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol